Opioid Analgesic Risk Evaluation
and Mitigation Strategy (REMS)

To manage serious risks associated with opioid analgesic products, the Food and Drug Administration (FDA) requires a REMS to ensure the benefits of these products outweigh the risks of addiction, abuse, and misuse. This REMS requires providers of opioid analgesics to offer REMS-compliant education programs for healthcare providers and strongly encourages HCPs to:

·         Complete an FDA REMS-compliant accredited continuing education (CE) program

·         Counsel the safe use, serious risks, storage, and disposal of opioid analgesics with patients and caregivers

·         Emphasize to patients and caregivers the importance of reading the Medication Guide provided by their pharmacist

·         Consider other tools to improve patient, household, and community safety

For further information and a list of accredited REMS CME/CE, call 1-800-503-0784 or visit www.opioidanalgesicrems.com.

For the FDA Blueprint, visit www.fda.gov/OpioidAnalgesicREMSBlueprint.